Arlon

Researchers are evaluating the safety and performance of remote monitoring functions in ALIZEA, BOREA, and CELEA pacemakers for patients with bradycardia. This observational clinical investigation focuses on the devices Right Atrial Autothreshold RAAT, Right Ventricular Autothreshold RVAT, and remote alert features. The study aims to document these functions over time to better understand their reliability and safety. Participants will be included soon after pacemaker implantation and followed for 48 months. Follow-up visits occur both on-site and remotely at 1 to 3 months, 6 months, 12 months, 24 months, and 48 months after inclusion. During these visits, the remote monitoring functions and the pacing systems performance will be measured, and safety will be continuously monitored throughout the study. Throughout the study, researchers will assess cardiac pacing thresholds, technical remote alerts, and the usability of the pacemaker and remote monitoring systems. Evaluations include Right Atrial and Right Ventricular pacing thresholds at multiple timepoints up to 48 months. Participants will undergo scheduled check-ins involving measurements, monitoring, and safety assessments, with the total study duration lasting four years after enrollment.

Researchers are evaluating the use of distal radial access DRA compared to conventional transradial access TRA for coronary catheterization procedures. This trial aims to assess whether advanced hemostasis methods and ultrasound-guided puncture can improve the success rate and reduce the time needed for hemostasis with DRA. This is important as DRA may offer safer vascular access with fewer complications, but its success rate and hemostasis duration require further study. The study compares several approaches use of a potassium ferrate hemostatic patch to enhance hemostasis in both distal radial and conventional transradial access, and the use of ultrasound guidance versus conventional guidance for distal radial access puncture. Participants will be randomly assigned to one of these methods. The study measures the duration of hemostasis from the end of the procedure and the success of vascular access placement. Participants will undergo coronary angiography or percutaneous coronary intervention with assigned access and hemostasis methods. Researchers will monitor hemostasis duration and access success, recording the time from anesthesia needle contact to sheath placement. Participants must have palpable radial pulses and meet other inclusion criteria. The total study period spans from enrollment through the procedure and hemostasis monitoring until completion, with no masking of treatment allocation.

Researchers are investigating the use of distal radial artery access compared to conventional radial artery access for complex large-bore percutaneous coronary interventions PCI in patients with complex coronary lesions such as chronic total occlusions, left main coronary artery disease, heavily calcified lesions, and complex bifurcations. This trial aims to evaluate the feasibility and safety of using a 7F Glidesheath Slender sheath for distal radial access, as limited data exist on its use for PCI in these complex cases. The study addresses the risk of radial artery occlusion and other vascular complications associated with different radial access sites. Participants will be randomly assigned to receive PCI through either distal radial access or conventional radial access, both using a 7F Glidesheath Slender sheath Terumo Corp., Japan. The study compares these two approaches during PCI with the Ultimaster family drug-eluting stent in complex coronary lesions. This trial is prospective, multicenter, and open-label, focusing on large-bore radial access and its impact on procedural success and vascular complications. During the study, participants will be monitored for radial artery occlusion and other access site complications up to hospital discharge, typically within five days after PCI. Assessments include clinical evaluation and Doppler ultrasound imaging. Researchers will also measure vascular access site bleeding, radial artery spasm, hemostasis time, pain, hand function up to one year, and target lesion failure at one year. Participants provide informed consent and are followed for outcomes relevant to vascular access safety and procedural success.

Human papillomavirus HPV infection is very common and often causes warts, which can appear at any age. This research investigates the effectiveness of two treatments, 2LVERU4 JUNIOR and 2LVERU4, compared to a placebo, in helping warts disappear. The study is placebo-controlled, randomized, and double-blind, aiming to see if these treatments improve wart clearance by the end of six months of treatment. Participants will take one capsule daily for six months, either 2LVERU4 JUNIOR or 2LVERU4, or a placebo, all taken on an empty stomach before breakfast. After the treatment phase, there is a three-month follow-up to monitor for any wart recurrence. Success is measured by normal skin color, texture, and touch at wart sites compared to the start of the study. During the study, participants will have regular assessments up to nine months from the start, including checking wart disappearance at four and six months and tracking any recurrence three months after treatment ends. Pain related to warts and safety through adverse event monitoring will also be evaluated. The study expects to enroll 162 patients aged three years and older with common, plantar, or flat warts.